Thursday, June 5, 2025
LBNN
  • Business
  • Markets
  • Politics
  • Crypto
  • Finance
  • Energy
  • Technology
  • Taxes
  • Creator Economy
  • Wealth Management
  • Documentaries
No Result
View All Result
LBNN

Replicate Bioscience Appoints Rachael Lester as Chief Business Officer

Simon Osuji by Simon Osuji
July 10, 2023
in Technology
0
Replicate Bioscience Appoints Rachael Lester as Chief Business Officer
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

 

Related posts

World Environment Day: UN sounds alarm on plastic pollution crisis, Kano urges collective action – EnviroNews

World Environment Day: UN sounds alarm on plastic pollution crisis, Kano urges collective action – EnviroNews

June 5, 2025
Weak winds key factor in 2023 extreme North Atlantic heatwave – Study – EnviroNews

Weak winds key factor in 2023 extreme North Atlantic heatwave – Study – EnviroNews

June 5, 2025

Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team


SAN DIEGO, July 10, 2023 /PRNewswire/ — Replicate Bioscience, Inc. company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, announced today that it has appointed Rachael Lester as its Chief Business Officer. Ms. Lester, who has more than 20 years of experience as a senior executive in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio strategy, and new product planning.


Rachael Lester, Chief Business Officer, Replicate Bioscience.


“I am delighted to welcome Rachael to the Replicate leadership team. Rachael has demonstrated an ability to drive growth and value at leading companies in our sector,” said Nathaniel Wang, Ph.D., Chief Executive Officer at Replicate. “Rachael is joining our organization at an important time, as we advance our robust pipeline of srRNA therapies into the clinic. Her leadership experience and proven track record in business development, sales and marketing, and finance will be invaluable for Replicate’s corporate growth, leveraging our srRNA platform to unlock novel therapeutic applications and bring new treatment options to patients worldwide.”


Ms. Lester joins Replicate from Harpoon Therapeutics (NASDAQ: HARP), a clinical-stage immunotherapy company, where she most recently served as Senior Vice President, Business Development and Corporate Strategy. In this role, she oversaw the company’s business development strategy and transactions, including global strategic partnerships with AbbVie and Roche, and supported multiple financings culminating in approximately $400M in dilutive and non-dilutive funding. Prior to her time at Harpoon, Ms. Lester served as Vice President of Product & Marketing for Bruin Biometrics where she drove commercialization into Europe, new product planning, and ongoing R&D collaborations and commercial distribution partnerships. Ms. Lester served as Global Head of Strategic Asset Management at Onyx Pharmaceuticals, where she was responsible for portfolio management, strategic finance, sell-side corporate development and innovation initiatives through the approvals of Kyprolis and Stivarga, and the $10.4B acquisition of Onyx by Amgen. At Deloitte Consulting, she held a leading role in the Life Sciences Strategy & Operations practice, as a thought leader and advisor to biotech clients on growth strategy, new product planning, and commercialization across a variety of transaction types (licensing, mergers, acquisitions, divestitures, spinouts). Ms. Lester received a B.A. in neuroscience from University of Pennsylvania and an M.B.A. from the Kellogg School of Management at Northwestern University.


“I’ve been following Replicate’s impressive progress to date and am enthusiastic to be joining an organization with such a distinct approach to overcoming traditional challenges in the development of RNA therapeutics,” said Ms. Lester. “I look forward to contributing my expertise to help advance Replicate’s patient-focused vision of enabling broadly accessible srRNA therapeutics.”


About Replicate Bioscience

Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA (srRNA) technology. Replicate’s off-the-shelf srRNAs contain two components: virally derived genetic code to drive controlled and self-limiting amplification, and the RNA encoding therapeutic proteins. The company’s library of viral vectors, selected for driving robust and sustained protein expression and orders-of-magnitude improved performance over linear mRNA, allow for the development of treatments in applications including oncology, infectious disease, and autoimmunity. Differentiated by a team of srRNA experts, a customizable library of synthetic srRNA vectors, and end-to-end development capabilities, Replicate is uniquely positioned to finally expand the reach of RNA treatments toward widespread use in infectious disease, immuno-oncology, autoimmune disease, and more. Visit us at replicatebioscience.com.


Replicate Bioscience (PRNewsfoto/Replicate Bioscience)


Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/replicate-bioscience-appoints-rachael-lester-as-chief-business-officer-301872292.html


SOURCE Replicate Bioscience

 

Source link

Previous Post

The six-billion-dollar post-human | E&ampT Magazine

Next Post

Top 6 Health and Safety Tips for Mobile Massage Therapists

Next Post

Top 6 Health and Safety Tips for Mobile Massage Therapists

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

Meta Used an App to Beat Snapchat’s Encryption: Court Docs

Meta Used an App to Beat Snapchat’s Encryption: Court Docs

1 year ago
22 Best Gifts for Cat Lovers (2024)

22 Best Gifts for Cat Lovers (2024)

6 months ago
8 Nations Opt For Chinese Yuan Amid De-Dollarization

8 Nations Opt For Chinese Yuan Amid De-Dollarization

3 weeks ago
Do You Think The World Would Be Safe If We All Decide To Reveal All The Evil People Have Done To Us? -Victoria Lebene To Yvonne Nelson

Do You Think The World Would Be Safe If We All Decide To Reveal All The Evil People Have Done To Us? -Victoria Lebene To Yvonne Nelson

2 years ago

POPULAR NEWS

  • Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    0 shares
    Share 0 Tweet 0
  • When Will SHIB Reach $1? Here’s What ChatGPT Says

    0 shares
    Share 0 Tweet 0
  • Matthew Slater, son of Jackson State great, happy to see HBCUs back at the forefront

    0 shares
    Share 0 Tweet 0
  • Dolly Varden Focuses on Adding Ounces the Remainder of 2023

    0 shares
    Share 0 Tweet 0
  • US Dollar Might Fall To 96-97 Range in March 2024

    0 shares
    Share 0 Tweet 0
  • Privacy Policy
  • Contact

© 2023 LBNN - All rights reserved.

No Result
View All Result
  • Home
  • Business
  • Politics
  • Markets
  • Crypto
  • Economics
    • Manufacturing
    • Real Estate
    • Infrastructure
  • Finance
  • Energy
  • Creator Economy
  • Wealth Management
  • Taxes
  • Telecoms
  • Military & Defense
  • Careers
  • Technology
  • Artificial Intelligence
  • Investigative journalism
  • Art & Culture
  • Documentaries
  • Quizzes
    • Enneagram quiz
  • Newsletters
    • LBNN Newsletter
    • Divergent Capitalist

© 2023 LBNN - All rights reserved.